Abeona Therapeutics (ABEO) Depreciation & Amortization (CF) (2011 - 2026)

Abeona Therapeutics' Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $690000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 29.21% year-over-year to $690000.0 in Q1 2026; TTM through Mar 2026 was $2.7 million, a 32.14% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 27.2% from the prior year.
• Depreciation & Amortization (CF) eased to $690000.0 in Q1 2026 per ABEO's latest filing, from $863000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $863000.0 in Q4 2025 and bottomed at $487000.0 in Q2 2024.
• The 5-year median for Depreciation & Amortization (CF) is $608000.0 (2025), against an average of $624941.2.
• Across the five-year window, Depreciation & Amortization (CF) slumped 33.21% in 2023 and jumped 60.11% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $729000.0 in 2022, then slumped by 32.65% to $491000.0 in 2023, then increased by 9.78% to $539000.0 in 2024, then soared by 60.11% to $863000.0 in 2025, then slipped by 20.05% to $690000.0 in 2026.
• Per Business Quant, the three latest ABEO Depreciation & Amortization (CF) figures stand at $690000.0 (Q1 2026), $863000.0 (Q4 2025), and $608000.0 (Q3 2025).